Cyberonics/ANS
This article was originally published in The Gray Sheet
Executive Summary
Advanced Neuromodulation Systems drops $524 mil., $22-per-share bid for vagus nerve stimulation developer Cyberonics Oct. 1. Cyberonics, which offers VNS Therapy for epilepsy and is seeking an expanded indication for depression, had spurned merger talks and rejected the offer as inadequate (1"The Gray Sheet" Sept. 20, 2004, p. 5)...
You may also be interested in...
Cyberonics Rejects Second ANS Bid, Considers Offer Beneath Self-Appraisal
Advanced Neuromodulation Systems likely would need to up the ante to sway Cyberonics shareholders to accept a takeover bid after CEO Skip Cummins' rejection of initial offers as too low
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.